Wyeth/Progenics Shoot For Early 2007 Methylnaltrexone NDA Submission
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth and partner Progenics plan to a submit an NDA by early 2007 for a new room-temperature formulation of subcutaneous methylnaltrexone for the treatment of opioid-induced side effects
You may also be interested in...
Wyeth, Progenics To Develop Methylnaltrexone Franchise
Companies plan to file NDAs for three formulations of the bowel dysfunction treatment over the next few years.
Wyeth, Progenics To Develop Methylnaltrexone Franchise
Companies plan to file NDAs for three formulations of the bowel dysfunction treatment over the next few years.
Wyeth Gains Phase III Candidate For Treatment Of Opioid Side Effects From Progenics
The $60 mil. deal gives Wyeth rights to three different dosage forms of methylnaltrexone for a range of opioid-induced conditions.